Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 5/20 | 0.36 |
| ▸ | INSR | P06213 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448591 | 0.93 | EGFR (0.38) | SYKCSNK2A1METINSREGFR | |
| SCHEMBL3448963 | 0.93 | SYK (0.36) | SYKEGFRAXL | |
| SCHEMBL3448714 | 0.92 | SYK (0.38) | SYKEGFRAXL | |
| SCHEMBL3447298 | 0.90 | RAF1 (0.38) | SYKCSNK2A1EGFRAXL | |
| SCHEMBL3448252 | 0.89 | CSNK2A1 (0.37) | SYKCSNK2A1METINSREGFR | |
| SCHEMBL3456772 | 0.89 | SYK (0.38) | SYKEGFRAXL | |
| SCHEMBL3454800 | 0.89 | SYK (0.42) | SYKEGFRAXL | |
| SCHEMBL3374414 | 0.89 | SYK (0.42) | SYKCSNK2A1METEGFRAXL | |
| SCHEMBL3448322 | 0.87 | SYK (0.39) | SYK | |
| SCHEMBL3448330 | 0.87 | AXL (0.36) | SYKEGFRAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | SYK 804/4885CSNK2A1 1858/4885MET 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.